Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be listed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, who are eligible for surgery, if the following conditions are met:
1. The duration of treatment with ulipristal acetate should not exceed three months.
2.The patient is under the care of an obstetrician/gynecologist.
3.The drug plan costs for ulipristal acetate should not exceed the drug plan costs for the manufacturer's identified comparator, leuprolide acetate. Indexing Status Subject indexing assigned by CRD MeSH Humans; Leiomyoma; Norpregnadienes Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000845 Date abstract record published 17/07/2014 |